The Federal Trade Commission’s interim report on the findings of its two-year investigation of pharmacy benefit managers flags “exclusionary rebating” as warranting further scrutiny as media reports surface that the commission may sue the three largest PBMs over their insulin contracting practices.
FTC’s PBM Investigation Could Yield Litigation Over Insulin Contracting
The US Federal Trade Commission’s focus on potential anti-competitive behavior by pharmacy benefit managers picks up steam as Chair Lina Khan approaches the end of her term.
